Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07893106) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight' on Oct. 19.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Ascletis Pharma (China) Co., Limited
Condition:
Chronic Weight Management
Intervention:
Drug: ASC36 tablets, for oral use
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: October 13, 2026
Target Samp...